[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rapport Therapeutics Inc (RAPP)

Rapport Therapeutics Inc (RAPP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,804,034
  • Shares Outstanding, K 47,827
  • Annual Sales, $ 0 K
  • Annual Income, $ -111,480 K
  • EBIT $ -122 M
  • EBITDA $ -123 M
  • 60-Month Beta 0.82
  • Price/Sales 79.07
  • Price/Cash Flow N/A
  • Price/Book 3.72

Options Overview Details

View History
  • Implied Volatility 72.05% (-4.58%)
  • Historical Volatility 55.49%
  • IV Percentile 4%
  • IV Rank 2.71%
  • IV High 295.21% on 08/29/25
  • IV Low 65.83% on 12/23/25
  • Expected Move (DTE 25) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 112
  • Volume Avg (30-Day) 48
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 216
  • Open Int (30-Day) 727
  • Expected Range 37.72 to 37.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.72
  • Number of Estimates 4
  • High Estimate $-0.26
  • Low Estimate $-0.92
  • Prior Year $-0.75
  • Growth Rate Est. (year over year) +4.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.41 +16.38%
on 04/30/26
40.80 -7.55%
on 05/08/26
+0.94 (+2.56%)
since 04/22/26
3-Month
26.01 +45.02%
on 03/19/26
40.92 -7.82%
on 04/17/26
+7.96 (+26.75%)
since 02/20/26
52-Week
7.73 +387.97%
on 05/30/25
42.27 -10.76%
on 09/08/25
+26.60 (+239.21%)
since 05/22/25

Most Recent Stories

More News
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 37.72 (+2.78%)
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12  ...

RAPP : 37.72 (+2.78%)
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical...

RAPP : 37.72 (+2.78%)
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 37.72 (+2.78%)
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026...

RAPP : 37.72 (+2.78%)
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

Partnership leverages Tenacia’s expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights...

RAPP : 37.72 (+2.78%)
Rapport Therapeutics to Participate in Upcoming Investor Conferences

BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 37.72 (+2.78%)
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter...

RAPP : 37.72 (+2.78%)
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 37.72 (+2.78%)
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’...

RAPP : 37.72 (+2.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 39.79
2nd Resistance Point 38.84
1st Resistance Point 38.28
Last Price 37.72
1st Support Level 36.77
2nd Support Level 35.82
3rd Support Level 35.26

See More

52-Week High 42.27
Last Price 37.72
Fibonacci 61.8% 29.07
Fibonacci 50% 25.00
Fibonacci 38.2% 20.92
52-Week Low 7.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.